Fox Run Management L.L.C. Buys 4,813 Shares of Insulet Corporation $PODD

Fox Run Management L.L.C. lifted its position in Insulet Corporation (NASDAQ:PODD) by 168.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,666 shares of the medical instruments supplier’s stock after buying an additional 4,813 shares during the quarter. Insulet makes up approximately 0.4% of Fox Run Management L.L.C.’s portfolio, making the stock its 11th biggest holding. Fox Run Management L.L.C.’s holdings in Insulet were worth $2,367,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PODD. Winnow Wealth LLC purchased a new stake in shares of Insulet in the third quarter worth $862,000. Illinois Municipal Retirement Fund raised its holdings in shares of Insulet by 41.3% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock valued at $3,780,000 after acquiring an additional 3,514 shares in the last quarter. Machina Capital S.A.S. bought a new stake in shares of Insulet during the 3rd quarter valued at about $2,778,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Insulet during the 2nd quarter valued at about $1,081,000. Finally, Jump Financial LLC grew its holdings in shares of Insulet by 12.0% during the second quarter. Jump Financial LLC now owns 66,170 shares of the medical instruments supplier’s stock worth $20,789,000 after purchasing an additional 7,070 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PODD shares. Jefferies Financial Group boosted their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Canaccord Genuity Group cut their target price on shares of Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Stifel Nicolaus lowered their price target on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Wells Fargo & Company lifted their price target on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Raymond James Financial reduced their price objective on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $354.57.

Insulet Stock Down 1.7%

Shares of NASDAQ:PODD opened at $245.25 on Wednesday. The stock has a market capitalization of $17.26 billion, a P/E ratio of 70.07, a price-to-earnings-growth ratio of 1.49 and a beta of 1.41. The stock’s 50-day moving average price is $270.73 and its 200-day moving average price is $304.34. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.Insulet’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.15 EPS. On average, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.